دورية أكاديمية
أعرض في EDS

Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials.

التفاصيل البيبلوغرافية
العنوان: Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials.
المؤلفون: Gomes MPB; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Linhares JHR; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Dos Santos TP; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Pereira RC; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Santos RT; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., da Silva SA; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Souza MCO; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., da Silva JFA; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Trindade GF; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Gomes VS; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Barreto-Vieira DF; Viral Morphology and Morphogenesis Laboratory, Oswaldo Cruz Institute/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Carvalho MMVF; Immunological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Ano Bom APD; Immunological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Gardinali NR; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Müller R; Pre-Clinical Trials Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Alves NDS; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Moura LDC; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Neves PCDC; Immunological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Esteves GS; Recombinant Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Schwarcz WD; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Missailidis S; Institute of Technology in Immunobiologicals, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., Mendes YDS; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil., de Lima SMB; Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil.
المصدر: Viruses [Viruses] 2023 Jun 30; Vol. 15 (7). Date of Electronic Publication: 2023 Jun 30.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: SARS-CoV-2* , COVID-19*/prevention & control, Mice ; Animals ; Antibody Formation ; Antibodies, Viral ; Immunization ; Enzyme-Linked Immunosorbent Assay ; Antibodies, Neutralizing
مستخلص: Successful SARS-CoV-2 inactivation allows its safe use in Biosafety Level 2 facilities, and the use of the whole viral particle helps in the development of analytical methods and a more reliable immune response, contributing to the development and improvement of in vitro and in vivo assays. In order to obtain a functional product, we evaluated several inactivation protocols and observed that 0.03% beta-propiolactone for 24 h was the best condition tested, as it promoted SARS-CoV-2 inactivation above 99.99% and no cytopathic effect was visualized after five serial passages. Moreover, RT-qPCR and transmission electron microscopy revealed that RNA quantification and viral structure integrity were preserved. The antigenicity of inactivated SARS-CoV-2 was confirmed by ELISA using different Spike-neutralizing monoclonal antibodies. K18-hACE2 mice immunized with inactivated SARS-CoV-2, formulated in AddaS0 3 TM , presented high neutralizing antibody titers, no significant weight loss, and longer survival than controls from a lethal challenge, despite RNA detection in the oropharyngeal swab, lung, and brain. This work emphasizes the importance of using different techniques to confirm viral inactivation and avoid potentially disastrous contamination. We believe that an efficiently inactivated product can be used in several applications, including the development and improvement of molecular diagnostic kits, as an antigen for antibody production as well as a control for non-clinical trials.
References: J Clin Microbiol. 1986 Oct;24(4):527-31. (PMID: 3021808)
PLoS One. 2021 Sep 15;16(9):e0256813. (PMID: 34525109)
Viruses. 2023 Feb 09;15(2):. (PMID: 36851694)
Science. 2020 Jul 3;369(6499):77-81. (PMID: 32376603)
Microsc Res Tech. 2022 Feb;85(2):562-569. (PMID: 34498784)
Viruses. 2021 Mar 26;13(4):. (PMID: 33810401)
Lancet Infect Dis. 2021 Jan;21(1):39-51. (PMID: 33069281)
Appl Environ Microbiol. 1997 Aug;63(8):3199-204. (PMID: 9251206)
Methods Mol Biol. 2022;2409:11-30. (PMID: 34709632)
J Clin Lab Anal. 2021 Apr;35(4):e23735. (PMID: 33608968)
Methods Mol Biol. 2009;510:329-36. (PMID: 19009272)
Histochem J. 1975 May;7(3):267-76. (PMID: 805108)
Pathogens. 2022 Feb 19;11(2):. (PMID: 35215213)
Vaccines (Basel). 2021 Nov 02;9(11):. (PMID: 34835197)
Clin Rev Allergy Immunol. 2005 Dec;29(3):333-44. (PMID: 16391410)
Vaccines (Basel). 2021 Mar 03;9(3):. (PMID: 33802467)
J Virol Methods. 2021 Apr;290:114087. (PMID: 33515663)
Nat Commun. 2021 Mar 2;12(1):1386. (PMID: 33654090)
J Virol Methods. 1987 May;16(1-2):21-8. (PMID: 3038939)
Viruses. 2022 Aug 31;14(9):. (PMID: 36146745)
J Gen Microbiol. 1964 Apr;35:75-80. (PMID: 14171261)
Vaccine. 2015 Aug 20;33(35):4261-8. (PMID: 25862300)
Virol Sin. 2021 Oct;36(5):879-889. (PMID: 33835391)
Virus Res. 2021 Nov;305:198555. (PMID: 34487766)
Lancet Infect Dis. 2021 May;21(5):637-646. (PMID: 33485468)
Expert Rev Vaccines. 2012 Jun;11(6):695-719. (PMID: 22873127)
Viruses. 2020 Jun 06;12(6):. (PMID: 32517266)
J Infect Dis. 2020 Oct 1;222(9):1462-1467. (PMID: 32798217)
iScience. 2021 Apr 23;24(4):102298. (PMID: 33723528)
Artif Cells Nanomed Biotechnol. 2018 Feb;46(1):33-38. (PMID: 29081252)
Appl Environ Microbiol. 2021 Sep 10;87(19):e0031421. (PMID: 34288702)
Emerg Microbes Infect. 2020 Dec;9(1):2606-2618. (PMID: 33241728)
Curr Opin Virol. 2012 Feb;2(1):84-9. (PMID: 22440970)
Mol Immunol. 2022 Jul;147:199-208. (PMID: 35644072)
Viruses. 2022 Aug 30;14(9):. (PMID: 36146723)
Viruses. 2020 Jul 07;12(7):. (PMID: 32646015)
Int J Infect Dis. 2004 Jan;8(1):21-5. (PMID: 14690777)
J Virol Methods. 2004 Oct;121(1):85-91. (PMID: 15350737)
فهرسة مساهمة: Keywords: K18-hACE2 transgenic mice; PRNT50; RT-qPCR; SARS-CoV-2 inactivation; TCID50; beta-propiolactone; immune response; non-clinical trials; serial passages
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Antibodies, Neutralizing)
تواريخ الأحداث: Date Created: 20230729 Date Completed: 20230731 Latest Revision: 20230803
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10386713
DOI: 10.3390/v15071486
PMID: 37515173
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4915
DOI:10.3390/v15071486